RD0101

RD0101 is a small molecule generic drug candidate being developed by **Pharmgen Science** (formerly Woori Pharmaceutical) for the treatment of **hyperlipidemia**. It is currently listed in the company's pipeline under the 'First Generic' category, indicating that it is a generic version of a reference drug for which Pharmgen Science aims to be among the first to market in South Korea. As a generic candidate, it is designed to be bioequivalent to an existing approved therapy for managing cholesterol and other lipid levels, although the specific reference product has not been publicly identified in the company's high-level pipeline disclosures.